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Ectopic expression of prion protein (PrP) in T lymphocytes or
hepatocytes of PrP knockout mice is insufficient to sustain prion
replication
Abstract
The cellular form of the Prion protein (PrPC) is necessary for prion replication in mice. To determine
whether it is also sufficient, we expressed PrP under the control of various cell- or tissue-specific
regulatory elements in PrP knockout mice. The interferon regulatory factor-1 promoter/Emu enhancer
led to high PrP levels in the spleen and low PrP levels in the brain. Following i.p. scrapie inoculation,
high prion titers were found in the spleen but not in the brain at 2 weeks and 6 months, showing that the
lymphoreticular system by itself is competent to replicate prions. PrP expression directed by the Lck
promoter resulted in high PrP levels on T lymphocytes only but, surprisingly, did not allow prion
replication in the thymus, spleen, or brain following i.p. inoculation. A third transgenic line, which
expressed PrP in the liver under the control of the albumin promoter/enhancer-albeit at low levels-also
failed to replicate prions. These results show that expression of PrP alone is not sufficient to sustain
prion replication and suggest that additional components are needed.
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hepatocytes of PrP knockout mice is insufficient to sustain
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ABSTRACT The cellular form of the Prion protein (PrPC)
is necessary for prion replication in mice. To determine whether
it is also sufficient, we expressed PrP under the control of various
cell- or tissue-specific regulatory elements in PrP knockout mice.
The interferon regulatory factor-1 promoteryEm enhancer led to
high PrP levels in the spleen and low PrP levels in the brain.
Following i.p. scrapie inoculation, high prion titers were found in
the spleen but not in the brain at 2 weeks and 6 months, showing
that the lymphoreticular system by itself is competent to replicate
prions. PrP expression directed by the Lck promoter resulted in
high PrP levels on T lymphocytes only but, surprisingly, did not
allow prion replication in the thymus, spleen, or brain following
i.p. inoculation. A third transgenic line, which expressed PrP in
the liver under the control of the albumin promoteryenhancer—
albeit at low levels—also failed to replicate prions. These results
show that expression of PrP alone is not sufficient to sustain
prion replication and suggest that additional components are
needed.
Though the major clinical and pathological manifestations of
prion diseases are found in the central nervous system, lymphoid
organs accumulate infectivity earlier than the brain even after
intracerebral (i.c.) inoculation (1–3). Although i.c. administration
of prions constitutes the most effective route of infection, pe-
ripheral, and in particular oral, uptake of prions is epidemiolog-
ically more relevant, as in the case of bovine spongiform enceph-
alopathy (BSE), sheep scrapie, kuru, and likely new variant
Creutzfeldt–Jakob disease (nvCJD).
It is not known which cell types in the spleen (LRS) are targets
for the scrapie agent. Involvement of follicular dendritic cells
(FDCs) has been postulated based on immunohistochemical
detection of the scrapie form of the prion protein (PrPSc) in these
cells (4–6). In scrapie-infected mice, infectivity was associated
with splenic B and T lymphocytes, but was not detected in
peripheral blood leukocytes (A.J.R., M.A.K., R. Frigg, E. Flech-
sig, A.A., and C.W., unpublished results). Transport of prions
from the periphery to the central nervous system is defective in
mice devoid of mature B lymphocytes (7), not necessarily because
B lymphocytes are directly involved in transport of prions, but
perhaps because no mature FDCs develop in the absence of B
lymphocytes (8–10).
Mice devoid of PrP (Prnp0/0) are resistant to scrapie and fail to
propagate prions (1, 11–13); susceptibility is regained by intro-
duction of PrP transgenes (1, 14). PrPC is also required for PrPSc-
induced neurotoxicity (15) and for prion spread within the central
nervous system (16).
In this report we describe the targeting of PrP expression to
three cell types or tissues in PrP null mice: splenocytes, T
lymphocytes, and hepatocytes. Expression controlled by a inter-
feron regulatory factor (IRF) 1 promoteryEm-enhancer gave high
levels of PrP in the spleen, particularly on B and T cells, but low
levels in the brain. Two weeks and 6 months after i.p. inoculation
with scrapie, high prion titers were found in the spleen and
thymus but not in the brain, showing that the lymphoreticular
system alone can sustain prion replication. However, Prnp0/0 mice
expressing PrP at high levels on T lymphocytes but not on B
lymphocytes failed to replicate prions in the spleen or thymus.
Expression of PrP in the liver, under the control of the albumin
promoter, failed to sustain prion replication in the liver, spleen,
or brain. Thus, PrPC expression alone is not sufficient to allow
prion replication.
MATERIALS AND METHODS
DNA Constructions. The ‘‘half-genomic’’ PrP vector (phgPrP),
pPrPcDNA, and pPrPE1i1E23R1 have been described (Fig. 1)
(14). To generate the promoterless ‘‘half-genomic’’ PrP vector
pPrP-59HG, a 2.7-kb PCR product was prepared using phgPrP as
the template, the 59-terminal primer pE1[ByT] (59-tgtcggatccag-
cagaccgattctgg-39) to introduce a unique BamHI site (italicized)
59 of exon 1, and the 39-terminal primer Del (59-tccccagcatgtagc-
caccaagg-39). The 2.3-kb BamHI-KpnI fragment of this PCR
product and the 1.3-kb fragment KpnI-EcoRI fragment of
pPrPE1i1E23R1 (comprising exon 2 and part of exon 3 with the
entire coding region) were joined to BamHI- and EcoRI-
restricted pBluescript. The resulting pPrP-59HG EcoRI was
digested with SalI and NarI and joined to the 3-kb NarI-SalI
fragment from phgPrP (comprising the 39 end of Prnp). plck-
PrP-59HG SalI: the 3.1-kb BamHI-NotI Lck promoter cassette
from p1017 (ref. 17; a gift from R. Perlmutter, Univ. of Wash-
ington, Seattle) was joined to NotI- and BamHI-cleaved pPrP-
59HG SalI. pEmyIRF1-PrP-59HG SalI: the human IRF1 pro-
moter was amplified by PCR from p-492IRF1cat (ref. 18; a gift
from H. Harada, Osaka Univ., Japan) using the 59 terminal
primer IRF top (59-tttctagaggagccaggctgc-39) containing an XbaI
site (italicized) and the 39-terminal primer IRF bottom (59-
agggatcctcgactaaggagtgg-39) with a BamHI site (italicized). The
560-bp XbaI-BamHI fragment of this PCR product and the 6-kb
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BamHI-SalI fragment from pPrP-59HG SalI were joined to the
3-kb XbaI-SalI fragment of pPrP-59HG SalI. The resulting
pIRF1-PrP-59HG SalI was linearized by partial XbaI digestion
and joined to a 2.1-kb XbaI fragment containing the Em Ig
heavy-chain enhancer from pEm-myc (ref. 19; a gift from T.
Taniguchi, Univ. of Tokyo, Japan). pAlbumin-PrP-59HG SalI:
the albumin promoteryenhancer was excised from plasmid
2335A-1 [equivalent to the construct NB (20), provided by R.
Palmiter, Univ. of Washington, Seattle] as a 2.0-kb BamHI-NotI
fragment and joined to the NotI- and BamHI-restricted pPrP-
59HG SalI.
Generation of Transgenic Mice. Plasmid DNA was digested
with NotI and SalI and microinjected into homozygous Prnp0/0
zygotes (14). Founders were identified by Southern analysis using
PrP ORF probe A (21). Prnp0 alleles and Prnp1 transgenes were
detected by PCR (14). Of seven mouse lines transgenic for the
albumin construct, two with the highest PrP mRNA levels in the
liver (Tg01yalb and Tg19yalb), of five lines transgenic for the lck
construct, two with highest PrP mRNA levels in the thymus
(Tg33ylck and Tg71ylck), and of three lines transgenic for the
EmyIRF1 construct, two with the highest PrP-expression levels in
the spleen (Tg94yIRF and Tg90yIRF), were maintained.
Immunoprecipitation. Tissue homogenates (10% wtyvol in 10
mM TriszHCl, pH 8.0y140 mM NaCl [Tris-buffered saline (TBS)]
containing 2% N-lauroylsarcosine and 1 mM phenylmethylsul-
fonyl fluoride) were centrifuged at 2000 3 g for 15 min. Super-
natants were diluted 5-fold in TBS, cleared, and incubated with
excess Sepharose 4B-linked monoclonal antibody 6H4 (22) for 2 h
at 4°C. The beads were washed in TBSy0.2% N-lauroylsarcosine,
TBSy0.5 M NaCly0.2% Nonidet P-40, TBSy0.5% Nonidet P-40,
and TBS, boiled in SDS-sample buffer, and the eluate was
immunoblotted.
Immunoblot Analysis. Tissue homogenates were analyzed as
described previously (23). Where indicated, samples (40 mg of
protein) were digested with 500 units of N-glycosidase F (New
England Biolabs) for 2 h at 37°C as recommended by the
manufacturer. PrP was detected with the polyclonal antibody 1B3
(24) diluted 1:10,000 and horseradish peroxidase-conjugated
swine anti-rabbit Igs, diluted 1:5000 (Dako) and developed using
the enhanced chemiluminescence kit (Amersham). An appropri-
ate exposure was scanned with a laser densitometer (Molecular
Dynamics) and quantified with IMAGEQUANT software.
Immunocytochemistry. Immunofluorescence staining on con-
secutive 5-mm cryosections and double-color immunofluores-
cence were performed with polyclonal anti-PrP rabbit antiserum
R340 (15) diluted 1:800 and biotinylated peanut agglutinin (1:400
dilution, Vector Laboratories) or with follicular dendritic cell
marker FDC-M1 (clone 4C11, 1:300 dilution) on frozen acetone-
fixed spleen sections. PrP and FDC-M1 were visualized by
immunofluorescence using the Tyramide Signal Amplification kit
(NEN) with Texas Red-conjugated avidin (1:100 dilution, Rock-
land, Gilbertsville, PA) and f luorescein isothiocyanate-
conjugated streptavidin (1:100 dilution, Serotec).
Scrapie Infection. Inoculum stock was a 10% (wtyvol) homog-
enate of Rocky Mountain Laboratory (RML; ref. 25) scrapie-
infected CD-1 mouse brains in 0.32 M sucrose. Mice were
infected i.p. with 100 ml of a 10-fold dilution of the RML stock in
PBS containing 5% BSA.
Titration of Infectivity. Prion titers were estimated from incu-
bation time to appearance of disease (26). Swiss CD-1 or ho-
mozygous Tg20 mice (14) mice were inoculated i.c. into the right
parietal lobe with 30-ml samples.
RESULTS
Mice Overexpressing PrP under the Control of the IRF1-
PromoteryIg Heavy-Chain Enhancer. Because prions accumulate
early on in the LRS, particularly in the spleen, we undertook to
overexpress PrP ectopically in various compartments of the LRS.
To validate the approach, we placed the PrP coding sequence
under the control of the IRF1-promoteryIg heavy-chain enhancer
(Em) which was reported to overexpress linked reading frames in
B and T lymphocytes (27). Two transgenic Prnp0/0 mouse lines
carrying this construct, Tg94yIRF and Tg90yIRF, were estab-
lished with transgene copy numbers of 6 and 4, respectively. PrP
mRNA levels in Tg94yIRF spleen and thymus were about 5 and
3 times higher, respectively, than in their wild-type counterparts
(data not shown); surprisingly, PrP in Tg94yIRF spleen was
.1,000 times higher than in wild-type spleen and PrP in Tg94yIRF
thymus was .100 times higher than in wild-type thymus (Table 1).
PrP on the surface of peripheral blood leukocytes, as determined
by fluorescence-activated cell sorter (FACS) analysis, was about
10-fold higher in Tg94yIRF than in wild-type mice (Fig. 2C). High
levels of PrP were also observed on B and T lymphocytes of
Tg94yIRF splenocytes (Fig. 2A). PrP in Tg94yIRF brain was 0.05
times that in wild-type brain (Table 1).
Cryosections of spleen from noninfected wild-type, Prnp0/0,
and Tg94yIRF mice were doubly stained for germinal center B
cells [with peanut agglutinin (28), green] and PrP (with PrP
antiserum 340, Texas red). In wild-type spleens, PrP was mainly
present in germinal centers, whereas in Tg94yIRF spleens it was
uniformly distributed over white and red pulp (Fig. 2D). As shown
in Fig. 2E, consecutive spleen sections were labeled with the
FDC-specific antibody M1 (green) and PrP antiserum (Texas
red), again revealing a striking overlap of FDC and PrP staining
within germinal centers in wild-type spleens. In Tg94yIRF
spleens, FDCs were stained in the germinal centers whereas
PrP-specific fluorescence was uniform over the whole section,
which is compatible with the FACS analysis showing that B and
T lymphocytes expressed PrP, and with the assumption that
FDCs also expressed PrP.
Transgenic, wild-type (129ySv-C57BLy6), and Prnp0/0 mice
were inoculated i.p. with 106 LD50 units of the RML isolate of
mouse prions. As shown in Table 1, all wild-type mice developed
scrapie after 194 6 5 days and died after 205 6 9 days, whereas
all Prnp0/0 mice remained healthy for more than 500 days. All of
7 Tg94yIRF mice hemizygous for the transgene cluster developed
scrapie symptoms after 452 6 15 days and died after 507 6 27
days, presumably because they expressed PrP in the brain, albeit
at low levels (data not shown). When rendered homozygous for
the transgene cluster, Tg94yIRF mice became ill with scrapie at
268 6 24 days after inoculation and died after 281 6 26 days
(Table 1).
Wild-type and Tg94yIRF mice hemizygous for the transgene
cluster were inoculated i.p. As shown in Table 2, 2 weeks after
FIG. 1. Schematic representation of half-genomic PrP transgenes
driven by heterologous promoters. The genomic mouse Prnp locus is
shown on top (37). Construction of the ‘‘half-genomic’’ PrP vector
(phgPrP) lacking the 12-kb intron 2 has been described (14). Using PCR
with the primers PE1 and Del, a BamHI site was introduced at the 59 end
of exon 1 in phgPrP. The resulting promoterless construct pPrP-59HG
EcoRI was cloned into Bluescript, and the PrP sequence was extended up
to the SalI site in the 39 noncoding region by introducing the NarI-SalI
fragment of phgPrP to yield pPrP-59HG SalI. Promoter cassettes were
inserted into the BamHI site of pPrP-59HG SalI to yield plck-PrP-59HG
SalI, pEmyIRF1-PrP-59HG SalI, and pAlbumin-PrP-59HG SalI. B,
BamHI; K, KpnI; N, NarI; Nt, NotI; R, EcoRI; S, SalI; X, XbaI. Wavy
lines, vector sequences.
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inoculation, spleen extracts from Tg94yIRF mice and wild-type
animals had the same titer: '7 log LD50 unitsyml 10% homog-
enate and no detectable infectivity in brain. Six months after
inoculation, the titers of Tg94yIRF spleen extracts were essen-
tially unchanged, somewhat higher than the value of 6.5 for
wild-type spleen; no infectivity was detected in Tg94yIRF brains
compared with 8 log LD50 unitsyml 10% homogenate for wild-
type brains. However, 1 year after inoculation, extracts from
hemizygous Tg94yIRF thymus, spleen, and brain showed prion
titers of about 5.5, 5, and 7 log LD50 unitsyml 10% homogenate,
respectively. The late appearance of prions in the brain is attrib-
uted to low-level PrP expression in Tg94yIRF brains.
Mice Overexpressing PrP on T Lymphocytes under the Con-
trol of the Lck Promoter. Two lines with the T lymphocyte-
specific Lck promoter construct, Tg33ylck and Tg71ylck, har-
bored 20 and 10 copies of the transgene, respectively. PrP-
transcript levels in the thymus were at least 50-fold higher than in
the wild-type thymus (data not shown). Significant levels of PrP
mRNA were also found in the spleen and kidney. Low levels of
PrP transcripts were detected in the brain, lung, and intestine only
upon longer exposure of the Northern blot (data not shown).
Tg33ylck thymus and spleen had PrP levels that were at least
100-fold and 40-fold higher, respectively, than in wild-type thy-
mus and spleen. PrP was undetectable in Tg33ylck brain (Fig.
3A). The high-level PrP expression in Tg33ylck thymocytes was
confirmed by FACS analysis (Fig. 2B) and estimated to be 50
times that in wild-type thymocytes. No PrP expression was
detected on Tg33ylck splenic B lymphocytes, whereas splenic T
lymphocytes were strongly positive for PrP (Fig. 2A). Immuno-
histochemical analysis of Tg33ylck spleens (Fig. 2E) showed that
PrP expression (Texas red) was predominantly in the perifollicular
T cell area, whereas the germinal centers, where the FDCs (green)
were located, showed little red fluorescence over background.
PrP from Tg33ylck thymus had a distinctly lower electro-
phoretic mobility on SDS-polyacrylamide gels than that of
Prnp1/1 brain (Fig. 3A). After deglycosylation with N-glycosidase
F, PrP from both spleen and thymus of Tg33ylck mice was
reduced to a single PrP species with about the same mobility as
recombinant PrP from Escherichia coli, i.e., an apparent molec-
ular mass of about 27 kDa (Fig. 3B). This confirmed that PrP
undergoes organ- andyor cell-specific glycosylation.
To determine whether PrPC expression on T lymphocytes of
Tg33ylck mice enabled prion replication in the thymus and
spleen, we assayed tissue homogenates pooled from two animals
sacrificed at 2 weeks, 6 months, and 12 months after i.p. inocu-
lation. In the case of Tg33ylck mice 2 weeks after inoculation,
spleen homogenates led to disease in 2 of 4 indicator mice after
192 6 39 days, whereas thymus homogenates caused disease in 1
of 4 indicator mice after 181 days. No infectivity was detected in
the spleen, thymus, or brain 6 or 12 months after inoculation,
except for a spleen extract collected 1 year after inoculation,
which led to scrapie in 1 of 4 CD-1 mice (Table 2). Thymus and
liver homogenates from Prnp0/0 mice also occasionally led to
disease in one or two of four indicator mice. These borderline
infectivities are likely due to prions persisting from the inoculum
(13, 29). Six months after i.p. inoculation, wild-type mice had
titers of about 6.5, 4.5, and 8 log LD50 unitsyml 10% homogenate
in the spleen, thymus, and brain, respectively.
Thus, even vast overexpression of PrPC on T lymphocytes,
comparable to levels found in wild-type brain, is not sufficient to
allow prion replication in the thymus or spleen of Prnp0/0 mice.
Mice Overexpressing PrP under the Control of the Albumin
Promoter. Transgenic mice with ectopic expression of PrP in the
liver were generated with use of the albumin enhancerypromoter
(20). Two lines, Tg01yalb and Tg19yalb, harbored 20 and 2
copies, respectively, of the hybrid transgene. Northern blot anal-
ysis of Tg01yalb tissues revealed high levels of PrP mRNA in the
liver and low levels in the lung, brain, and kidney (data not
shown). PrP levels in Tg01yalb liver were at least 5-fold higher
than those in wild-type liver, but still about 2–3 times lower than
in wild-type spleen (Fig. 3C). PrP levels in Tg01yalb brain were
about 10% of those in Prnp1/1 brain. None of the Tg01yalb mice
developed scrapie disease within 400 days of i.p. inoculation
(Table 1) or within 300 days of i.c. inoculation.
No infectivity was detected in the liver, brain, or spleen of
Tg01yalb mice at any time after inoculation (Table 2). Liver
extracts of Prnp1/1 and Prnp0/0 mice occasionally caused disease in
one or two indicator mice, especially early after inoculation and
likely due to residual inoculum. Thus, PrP expression in the liver
Table 1. Characteristics of transgenic mouse lines
Line
PrP-encoding
gene (copy no.*)
PrP RNA
(organ)†
PrP protein
(organ)†
Days to
symptoms‡
(no. of animals§)
Prnp1y1 Prnp (2) 194 6 5 (14y14)
1 (br) 1 (br)
1 (spl) 1 (spl)
1 (thy) 1 (thy)
Prnp0y0 – – – .500 (0y10)
Tg94yIRF EmyIRF1-PrP (6) 5 (spl) .1000 (spl) 268 6 24 (18y18)
0.2 (br) ,0.05 (br)
3 (thy) .100 (thy)
Tg33ylck lck-PrP (20) .500 (0y6)
2 (spl) 40 (spl)
0.025 (br) ,0.001 (br)
40 (thy) .100 (thy)
Tg01yalb alb-PrP (20) .400 (0y6)
11 (liv) 5 (liv)
0.09 (br) 0.1 (br)
0 (spl) ND
0 (thy) ND
*Relative to wild-type; determined by Southern blot analysis. All transgenic animals were homozygous
for the transgene and all mice had a mixed 129SvyC57Bl background.
†Relative to the corresponding wild-type organ (br, brain; spl, spleen; thy, thymus; liv, liver); determi-
nation of PrP mRNA by quantitative Northern blot analysis, and of PrP by densitometry of Western blots.
ND, not determined.
‡Animals were inoculated i.p. with 100 ml of a 1% (wtyvol) brain homogenate (RML isolate).
§Number of mice developing scrapieytotal number of mice inoculated.
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of Prnp0/0 mice, at least at the level achieved—about one-third that
found in wild-type spleen—was not sufficient to allow prion
replication.
Prions Are Replicated in the LRS. Although high prion titers
were found in the spleen within days after i.c. or i.p. inoculation,
it was not immediately clear whether this reflects de novo synthesis
in the LRS or the scavenging of infectious agent generated in the
brain or derived from the inoculum. Inoculation with very low
prion doses resulted in a net increase of infectious agent in the
spleen (30); however, it could not be excluded that the agent was
synthesized in the brain and transported to the LRS. To resolve this
question, we inoculated Tg94yIRF mice i.p. with a low dose of
RML prions (3.5 log LD50 i.c. units) and determined prion titers
in the spleen by endpoint titration (Table 3). Titers (in log LD50 i.c.
unitsyml 10% homogenate) rose from 2 at 2 weeks after inocu-
lation to about 6 after 4 weeks and remained at this level for up to
12 weeks. Because a spleen weighs about 100 mg, this represents
an increase of at least 2.5 log units over input, showing that prions
are replicated in the spleen of i.p. inoculated Tg94yIRF mice and
are not due to residual inoculum or import from the brain, which
even at 6 months contains no detectable infectivity.
DISCUSSION
We have used ectopic expression of PrP in Prnp0/0 mice to
investigate whether the presence of PrP in a particular tissue
suffices to restore prion replication. Prion titers were low or
E
D
A
B
C
FIG. 2. Analysis of PrP expression by FACS and immunohistochemistry. FACS analysis for cell-surface PrP was carried out on (A) splenocytes, (B)
thymocytes, and (C) peripheral blood leukocytes (PBL) gated for lymphocytes from Prnp1/1, Prnp0/0, Tg94yIRF, and Tg33ylck mice. Cells were stained
with anti-PrP polyclonal antisera R340 and phycoerythrin-conjugated anti-rabbit IgG, and analyzed by FACS gated for lymphocytes. (A) For two-color
FACS analysis, PrP staining was followed by B cell staining with FITC-conjugated anti-B220 antibodies or T cell staining with FITC-conjugated anti-CD3
antibodies. (D) Double immunofluorescence analysis of splenic germinal centers in noninoculated Tg94yIRF (a–d), wild-type mice (e–h), and Prnp0/0
mice (j–m). Sections were stained with haemalaun (a, e, j), with peanut agglutinin (PNA; green; b, f, k), and with antiserum R340 to PrP (Texas red; c,
g, l). The majority of B cells PNA labeled in the germinal center were PrP-positive in Tg94yIRF mice (yellow signal in superimposed images; d) and in
wild-type mice (h), but PrP-negative in Prnp0/0 mice (m). (Original magnification 3250.) (E) Immunofluorescence labeling of FDCs and PrP on consecutive
sections of spleen from noninoculated Tg94yIRF (a–d), Tg33ylck (e–h), wild-type (j–m), and Prnp0/0 mice (n–q). Sections were stained with haemalaun
(a, e, j, n), antibody FDC-M1 to FDC (green; b, f, k, o), antiserum R340 to PrP (Texas red; c, g, l, p), and rabbit pre-immune serum (PIS; d, h, m, q).
In wild-type spleens (k, l), PrP was stained exclusively in the germinal centers, most strongly in the areas also stained by FDC-M1. In Tg94yIRF mice
(b, c), PrP was evenly distributed over the entire section, including the region also stained by FDC-M1. In Tg33ylck spleens, PrP was visualized mainly
in the T cell areas, but some cells were stained in the region also stained by FDC-M1. No PrP staining above background (q) was found in germinal centers
of Prnp0/0 mice (p). (Original magnification 3250.)
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absent in the liver of scrapie- or CJD-agent-infected mice (2, 31),
which may be attributed to the very low levels, if any, of PrP in
the liver (32). By immunopurification with the anti-PrP mono-
clonal antibody 6H4 (22), we detected PrP at very low but
significant levels in the liver of wild-type but not of Prnp0/0 mice,
but did not distinguish whether it was in hepatocytes or in cells of
the LRS. Expression in liver of Prnp0/0 mice of the PrP coding
sequence under the control of the albumin promoteryenhancer
led to PrP levels about 5-fold higher than those in wild-type mice,
but i.p. inoculation did not lead to infectivity in the liver for as long
as 1 year after inoculation. This may be because hepatocytes lack
some factor(s) required for prion replication. Alternatively, the
expression level might be too low to sustain prion replication; it
is, however, only 2–3 times lower than in wild-type spleen, where
prions are replicated efficiently. Although Tg01yalb mouse brain
contained PrP at about 10% of the level found in wild-type brain,
it remained devoid of infectivity for as long as 1 year after i.p.
inoculation, perhaps because prions are unable to invade the
central nervous system (and the liver) in the absence of a
PrP-containing LRS (33).
Because the spleen was reported to efficiently replicate prions
after i.p. as well as after i.c. inoculation (30, 34), targeting
individual cell types of the LRS was an attractive goal. Although
the heterologous EmyIRF1 enhancerypromoter was intended to
target the LRS, PrP mRNA was detected also in other tissues,
particularly in the brain; within the intestine, expression may well
have been in the lymphoreticular compartment. PrP expression in
the spleen of Tg94yIRF mice was .20-fold higher than in
wild-type brain and .1000-fold higher than in wild-type spleen.
In wild-type mice, PrP levels in the brain exceeded those in spleen
by '100-fold. In the spleen, PrP was detected on B and T
lymphocytes; expression on FDCs is likely judged by the finding
of PrPC in the stroma of uninfected Tg94yIRF mice and of PrPSc
in that of infected Tg94yIRF mice, as well as by the uniform
immunostaining of PrP across the germinal centers.
FIG. 3. Immunoblot analysis for PrP in tissues of various mouse lines.
(A) Aliquots (120 mg of protein) of tissue homogenates as indicated were
loaded per lane. (B) Aliquots (40 mg of protein) of tissue homogenates
were digested with 500 units of N-glycosidase F for 2 h at 37°C. (C)
Aliquots of tissue homogenates as indicated were immunoprecipitated
with 6H4 monoclonal antibody coupled to Sepharose 4B. The eluted
proteins were subjected to Western blotting and PrP was detected on blots
with 1:10,000 diluted polyclonal anti-PrP antiserum 1B3. Molecular mass
markers are indicated on the left in kDa.
Table 2. Infectivity bioassay of organs from RML-inoculated mice
Donor*
Time p.i.,
days Organ†
Death,
days nynt‡ Titer§
Prnp1y1 14 Brain .300 0y4
14 Spleen 1636 4 4y4 7
14 Thymus 200624 4y4 3.5
14 Liver 250 1y4 '1
180 Brain 1506 4 4y4 8
180 Spleen 1686 5 4y4 6.5
180 Thymus 189623 4y4 4.5
180 Liver .300 0y4
Prnp0y0 14 Brain .300 0y4
14 Spleen .300 0y3¶
14 Thymus 295 1y4 '1
14 Liver 247652 2y4 '1.5
180 Brain .300 0y4
180 Spleen .300 0y4
180 Thymus .300 0y4
180 Liver 240 1y4 '1
365 Brain .300 0y4
365 Spleen .300 0y4
365 Thymus .300 0y3¶
365 Liver .300 0y3¶
Tg33ylck (hemi) 14 Brain .300 0y4
14 Spleen 195641 2y4 '1.5
14 Thymus 189 1y4 '1
180 Brain .300 0y4
180 Spleen .300 0y4
180 Thymus .300 0y3¶
365 Brain .300 0y4
365 Spleen 222 1y4 '1
365 Thymus .300 0y4
Tg01yalb (hemi) 14 Brain .300 0y4
14 Spleen .300 0y4
14 Liver .300 0y4
180 Brain .300 0y4
180 Spleen .300 0y4
180 Liver .300 0y4
365 Brain .300 0y4
365 Spleen .300 0y4
365 Liver .300 0y4
Tg94yIRF (hemi) 14 Brain .300 0y4
14 Spleen 163612 4y4 7
180 Brain .300 0y4
180 Spleen 1606 6 4y4 7
365 Brain\ 666 2 4y4 7
365 Spleen\ 866 5 4y4 5
365 Thymus\ 816 8 4y4 5.5
*hemi, hemizygous for the transgene.
†Ten percent organ homogenates in 0.32 M sucrose were diluted
10-fold in PBSy5% BSA and 30 ml of the 1% homogenate was
inoculated i.c. into CD-1 mice.
‡Number of mice with scrapieytotal number of mice inoculated.
§Infectivity levels (log LD50yml 10% homogenate) were determined by
the incubation time method using standard curves for CD-1 (1) or Tg20
(15) mice. Limit of detection: '1 log LD50yml 10% homogenate.
¶One mouse died of intercurrent disease.
\Assayed in Tg20 mice.
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Following i.p. challenge with mouse prions, Tg94yIRF mice
maintained high titers of prions in the spleen from 2 weeks up to
6 months after inoculation without any infectivity appearing in
the brain. Although the PrP-expression level in Tg94yIRF spleen
was .1000-fold higher than in wild-type spleen, prion titers were
not significantly higher in Tg94yIRF than in wild-type spleen.
Moreover, although PrP expression in Tg94yIRF spleen was
about 20-fold higher than in the brain, prion titers in the brain
were 10-fold higher than in the spleen 12 months after i.p.
inoculation. This paradox can be explained if the high PrP levels
in Tg94yIRF spleen reflected PrP on B and T lymphocytes but
not on other spleen cells such as FDCs, and if prion replication
were limited by the latter.
In mice with Lck promoter-controlled PrP expression, PrP
levels on T lymphocytes of Tg33ylck mice were .100-fold and
.10-fold higher than those of Prnp1/1 and Tg94yIRF mice,
respectively. Following i.p. challenge with mouse scrapie prions,
Tg33ylck mice showed no disease and failed to replicate prions in
the spleen or brain. Because Tg94yIRF mice, which express high
levels of PrP on B and T lymphocytes (perhaps also on other cells
of the LRS), accumulate prions to high levels in spleen and
thymus, PrP expression on FDCs or other splenocytes appear to
be necessary for prion replication in the LRS. The strong expres-
sion of PrPC on FDCs of uninfected mice, as shown by immu-
nohistochemistry (Fig. 2E), further supports the role (5, 6)
ascribed to these cells in prion replication in the LRS.
Why do T lymphocytes overexpressing PrP not accumulate
prion infectivity? Perhaps they are devoid of a conjectural re-
ceptor required for prion uptake or lack cellular factor(s) re-
quired for prion replication. Experiments with transgenic mice
led to the suggestion that a species-specific factor X is required for
prion replication (35, 36). Alternatively, T lymphocytes are able
to replicate prions, but are either rapidly eliminated due to a
prion-elicited toxic effect, or ‘‘washed out’’ as a result of normal
turnover. Finally, it is possible that prions administered i.p. in a
PrP knockout environment are not transported or transferred to
T lymphocytes.
We have recently determined that both B and T lymphocytes
from the spleen, but not peripheral blood leukocytes, of scrapie-
infected wild type and Tg94yIRF mice carry scrapie infectivity
(A.J.R., M.A.K., R. Frigg, E. Flechsig, A.A., and C.W., unpub-
lished results). In conjunction with the findings reported in this
paper, this suggests that T lymphocytes cannot replicate prions on
their own, but either acquire them from a different cell type or
replicate them in dependence of other cells.
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Table 3. Titration of scrapie infectivity in spleens of Tg94yIRF mice inoculated i.p.
Time after i.p.
inoculation,
weeks
Days to disease in indicator mice (nyn0) at log dilution*
Titer†0 21 22 23 24 25
2
73 6 1
(4y4)
—
(0y4) ND ND ND ND 2
4 ND
79 6 5
(4y4)
84 6 6
(2y2)
104 6 2
(3y4)
121 6 4
(3y4)
—
(0y4) 6
8 ND
78 6 4
(4y4) ND
103 6 13
(4y4)
110
(1y4)
118
(1y4) 5
12 ND
71 6 0
(4y4) ND
94 6 7
(4y4)
111 6 11
(4y4)
—
(0y4) 6
Homozygous Tg94yIRF mice were inoculated i.p. with 3.5 log LD50 i.c. units of RML prions. At the times indicated, mice were killed and the
titer in the spleen was determined by endpoint titration in Tg20 mice. The numbers in the table indicate days elapsed to appearance of symptoms
and the fraction (nyn0) of mice falling sick. ND, not done.
*Serial 10-fold dilutions of 10% spleen homogenates were prepared in PBSy5% BSA and 30 ml was inoculated i.c. into Tg20 mice.
†log LD50 unitsyml 10% homogenate. Calculated by multiplying the LD50 units at the endpoint dilution with 333 dilution factor.
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